

Katja N Gaarenstroom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4646671/publications.pdf>

Version: 2024-02-01

60
papers

4,626
citations

147801

31
h-index

138484

58
g-index

61
all docs

61
docs citations

61
times ranked

5437
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. <i>Supportive Care in Cancer</i> , 2022, 30, 3409-3418.	2.2	1
2	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	1.6	25
3	Sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma: a proposed protocol for a multicentre observational study. <i>BMC Cancer</i> , 2022, 22, 445.	2.6	4
4	Changes in Sex Steroids and Relation With Menopausal Complaints in Women Undergoing Risk-reducing Salpingo-oophorectomy. <i>Journal of the Endocrine Society</i> , 2022, 6, bvac069.	0.2	5
5	Long-Term Morbidity and Health After Early Menopause Due to Oophorectomy in Women at Increased Risk of Ovarian Cancer: Protocol for a Nationwide Cross-Sectional Study With Prospective Follow-Up (HARMOny Study). <i>JMIR Research Protocols</i> , 2021, 10, e24414.	1.0	9
6	Evaluation of treatment, prognostic factors, and survival in 198 vulvar melanoma patients: Implications for clinical practice. <i>Gynecologic Oncology</i> , 2021, 161, 202-210.	1.4	8
7	The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks. <i>Cancers</i> , 2021, 13, 2994.	3.7	23
8	Abstract 364: The RAD51-FFPE test rapidly and reliably identifies homologous recombination deficient ovarian and endometrial carcinomas. , 2021, , .		0
9	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in <i>BRCA1/2</i> Pathogenic Variant Carriers. <i>JAMA Oncology</i> , 2021, 7, 1203.	7.1	27
10	Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II. <i>Journal of Clinical Oncology</i> , 2021, 39, 3623-3632.	1.6	69
11	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. <i>Gynecologic Oncology</i> , 2021, 163, 371-377.	1.4	2
12	The effect of hormone therapy on breast density following risk-reducing salpingo-oophorectomy in women with an increased risk for breast and ovarian cancer. <i>Menopause</i> , 2021, Publish Ahead of Print, 1307-1312.	2.0	2
13	Fertility-sparing surgery of cervical cancer >2 cm (International Federation of Gynecology and) Tj ETQq1 1 0.784314 rgBT /Overloc <i>Gynecological Cancer</i> , 2020, 30, 115-121.	2.5	27
14	Near-infrared fluorescence imaging compared to standard sentinel lymph node detection with blue dye in patients with vulvar cancer – a randomized controlled trial. <i>Gynecologic Oncology</i> , 2020, 159, 672-680.	1.4	26
15	Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. <i>Cancers</i> , 2020, 12, 1562.	3.7	9
16	The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas. <i>Cancers</i> , 2020, 12, 2805.	3.7	30
17	An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. <i>Nature Medicine</i> , 2019, 25, 838-849.	30.7	486
18	A patient decision aid for risk-reducing surgery in premenopausal <i>BRCA1/2</i> mutation carriers: Development process and pilot testing. <i>Health Expectations</i> , 2018, 21, 659-667.	2.6	17

#	ARTICLE	IF	CITATIONS
19	Folate receptor- α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study. <i>Oncotarget</i> , 2018, 9, 791-801.	1.8	32
20	Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 600-611.	2.8	18
21	Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 613-621.	1.6	103
22	A Woman with Changing Vulvar Anatomy: Sexuality in Women with Lichen Sclerosus. , 2017, , 329-341.		0
23	Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: A prospective study. <i>European Journal of Cancer</i> , 2017, 84, 159-167.	2.8	40
24	Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 146, 449-456.	1.4	15
25	Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 43-51.	2.5	195
26	Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. <i>Modern Pathology</i> , 2016, 29, 753-763.	5.5	230
27	Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers. <i>British Journal of Cancer</i> , 2016, 115, 1174-1178.	6.4	4
28	A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2929-2938.	7.0	218
29	Repeat sentinel lymph node procedure in patients with recurrent vulvar squamous cell carcinoma is feasible. <i>Gynecologic Oncology</i> , 2016, 140, 415-419.	1.4	30
30	Intraoperative imaging of folate receptor alpha positive ovarian and breast cancer using the tumor specific agent EC17. <i>Oncotarget</i> , 2016, 7, 32144-32155.	1.8	116
31	Prognostic value and clinicopathologic characteristics of L1 cell adhesion molecule (L1CAM) in a large series of vulvar squamous cell carcinomas. <i>Oncotarget</i> , 2016, 7, 26192-26205.	1.8	5
32	Sentinel Lymph Node Biopsy in Vulvar Cancer Using Combined Radioactive and Fluorescence Guidance. <i>International Journal of Gynecological Cancer</i> , 2015, 25, 1086-1093.	2.5	76
33	Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: A review of the current literature. <i>Gynecologic Oncology</i> , 2015, 136, 143-157.	1.4	85
34	Groin surgery and risk of recurrence in lymph node positive patients with vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2015, 139, 458-464.	1.4	20
35	Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. <i>BMC Cancer</i> , 2015, 15, 593.	2.6	88
36	The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer. <i>PLoS ONE</i> , 2015, 10, e0129766.	2.5	118

#	ARTICLE	IF	CITATIONS
37	CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma. <i>Gynecologic Oncology</i> , 2014, 135, 149-155.	1.4	52
38	Real-time near-infrared fluorescence guided surgery in gynecologic oncology: A review of the current state of the art. <i>Gynecologic Oncology</i> , 2014, 135, 606-613.	1.4	69
39	Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study. <i>BMC Cancer</i> , 2014, 14, 22.	2.6	37
40	Value-based healthcare in Lynch syndrome. <i>Familial Cancer</i> , 2013, 12, 347-354.	1.9	6
41	Intraoperative Near Infrared Fluorescence Guided Identification of the Ureters Using Low Dose Methylene Blue: A First in Human Experience. <i>Journal of Urology</i> , 2013, 190, 574-579.	0.4	147
42	Randomized comparison of near-infrared fluorescence lymphatic tracers for sentinel lymph node mapping of cervical cancer. <i>Gynecologic Oncology</i> , 2012, 127, 126-130.	1.4	73
43	Optimization of near-infrared fluorescent sentinel lymph node mapping for vulvar cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 206, 89.e1-89.e5.	1.3	76
44	Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study. <i>BMC Cancer</i> , 2012, 12, 31.	2.6	48
45	Quality of pathology reports for advanced ovarian cancer: Are we missing essential information?. <i>European Journal of Cancer</i> , 2011, 47, 57-64.	2.8	34
46	Optimization of Near-Infrared Fluorescent Sentinel Lymph Node Mapping in Cervical Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1472-1478.	2.5	72
47	Pelvic Actinomycosis-Like Disease Due to <i>Propionibacterium propionicum</i> after Hysteroscopic Removal of an Intrauterine Device. <i>Journal of Clinical Microbiology</i> , 2011, 49, 466-468.	3.9	10
48	Nerve Sparing in Radical Surgery for Early-Stage Cervical Cancer: Yes We Should!. <i>International Journal of Gynecological Cancer</i> , 2010, 20, S39-S41.	2.5	25
49	National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. <i>Clinical Chemistry</i> , 2010, 56, e1-e48.	3.2	184
50	Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. <i>Lancet Oncology</i> , 2010, 11, 646-652.	10.7	228
51	Nerve-Sparing Radical Hysterectomy: Local Recurrence Rate, Feasibility, and Safety in Cervical Cancer Patients Stage IA to IIA. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 39-45.	2.5	55
52	Sentinel Node Dissection Is Safe in the Treatment of Early-Stage Vulvar Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 884-889.	1.6	684
53	Predictors of Prophylactic Bilateral Salpingo-Oophorectomy Compared With Gynecologic Screening Use in BRCA1/2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2007, 25, 301-307.	1.6	73
54	The Impact of Hormone Replacement Therapy on Menopausal Symptoms in Younger High-Risk Women After Prophylactic Salpingo-Oophorectomy. <i>Journal of Clinical Oncology</i> , 2006, 24, 3576-3582.	1.6	186

#	ARTICLE	IF	CITATIONS
55	Sexual function after partial cystectomy and urothelial stripping in a 32-year-old woman with radiation cystitis. <i>International Urogynecology Journal</i> , 2005, 16, 412-414.	1.4	3
56	Quality-of-Life Effects of Prophylactic Salpingo-Oophorectomy Versus Gynecologic Screening Among Women at Increased Risk of Hereditary Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 6890-6898.	1.6	214
57	Can Initial Serum Cyfra 21-1, SCC Antigen, and TPA Levels in Squamous Cell Cervical Cancer Predict Lymph Node Metastases or Prognosis?. <i>Gynecologic Oncology</i> , 2000, 77, 164-170.	1.4	81
58	Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer. <i>Cancer</i> , 1995, 76, 807-813.	4.1	42
59	Prognostic significance of serum antibodies to human papillomavirus-16 E4 and E7 peptides in cervical cancer. <i>Cancer</i> , 1994, 74, 2307-2313.	4.1	18
60	HPV DNA Presence and HPV Genotypes as Prognostic Factors in Low-Stage Squamous Cell Cervical Cancer. <i>Gynecologic Oncology</i> , 1993, 48, 333-337.	1.4	46